CN1298328C - 包括应用zd6474和紫杉烷的联合疗法 - Google Patents

包括应用zd6474和紫杉烷的联合疗法 Download PDF

Info

Publication number
CN1298328C
CN1298328C CNB028267958A CN02826795A CN1298328C CN 1298328 C CN1298328 C CN 1298328C CN B028267958 A CNB028267958 A CN B028267958A CN 02826795 A CN02826795 A CN 02826795A CN 1298328 C CN1298328 C CN 1298328C
Authority
CN
China
Prior art keywords
taxane
pharmaceutically acceptable
warm
acceptable salt
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028267958A
Other languages
English (en)
Chinese (zh)
Other versions
CN1612738A (zh
Inventor
S·R·韦奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1612738A publication Critical patent/CN1612738A/zh
Application granted granted Critical
Publication of CN1298328C publication Critical patent/CN1298328C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB028267958A 2001-11-08 2002-11-06 包括应用zd6474和紫杉烷的联合疗法 Expired - Fee Related CN1298328C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0126879.6A GB0126879D0 (en) 2001-11-08 2001-11-08 Combination therapy
GB0126879.6 2001-11-08

Publications (2)

Publication Number Publication Date
CN1612738A CN1612738A (zh) 2005-05-04
CN1298328C true CN1298328C (zh) 2007-02-07

Family

ID=9925430

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028267958A Expired - Fee Related CN1298328C (zh) 2001-11-08 2002-11-06 包括应用zd6474和紫杉烷的联合疗法

Country Status (22)

Country Link
US (2) US20050043395A1 (https=)
EP (1) EP1446124B1 (https=)
JP (1) JP4694127B2 (https=)
KR (1) KR100959607B1 (https=)
CN (1) CN1298328C (https=)
AR (1) AR037346A1 (https=)
AT (1) ATE335488T1 (https=)
AU (1) AU2002337382B2 (https=)
BR (1) BR0213906A (https=)
CA (1) CA2464758C (https=)
CY (1) CY1106259T1 (https=)
DE (1) DE60213845T2 (https=)
DK (1) DK1446124T3 (https=)
ES (1) ES2269769T3 (https=)
GB (1) GB0126879D0 (https=)
IL (2) IL161744A0 (https=)
MX (1) MXPA04004355A (https=)
NO (1) NO328048B1 (https=)
NZ (1) NZ532525A (https=)
PT (1) PT1446124E (https=)
WO (1) WO2003039551A1 (https=)
ZA (1) ZA200403455B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397401A (zh) * 2016-08-30 2017-02-15 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法
CN106478598A (zh) * 2016-08-30 2017-03-08 山东罗欣药业集团股份有限公司 一种凡德他尼水合物晶体及其制备方法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100881105B1 (ko) * 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ES2267748T3 (es) 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
SI1474420T1 (sl) * 2002-02-01 2012-06-29 Astrazeneca Ab Spojine kinazolina
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
AU2003278383B2 (en) 2002-11-04 2007-06-14 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
KR20050100683A (ko) * 2003-02-13 2005-10-19 아스트라제네카 아베 5-ｆｕ 또는/및 ｃｐｔ-11과 ｚｄ6474의 병용 요법
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
WO2006002422A2 (en) * 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
PL1971338T3 (pl) * 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie ZD6474 i premetreksedu
EP2094268A2 (en) * 2006-05-26 2009-09-02 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
WO2010061208A2 (en) * 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
JP7737455B2 (ja) * 2020-12-22 2025-09-10 ハンミ ファーマシューティカル カンパニー リミテッド Ｓｏｓ１阻害剤としての新規キナゾリン誘導体化合物及びその用途｛ｎｏｖｅｌ ｑｕｉｎａｚｏｌｉｎｅ ｄｅｒｉｖａｔｉｖｅｓ ａｓ ｓｏｓ１ ｉｎｈｉｂｉｔｏｒｓ ａｎｄ ｕｓｅ ｔｈｅｒｅｏｆ｝

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032651A1 (en) * 1999-11-05 2001-05-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
PT910382E (pt) * 1996-04-26 2003-10-31 Genaera Corp Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
MXPA01008699A (es) * 1999-02-24 2002-06-21 Uab Research Foundation Derivados de taxano para terapia de cancer dirigida. .
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
AU2003249000B2 (en) * 2002-08-09 2007-04-05 Astrazeneca Ab Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
KR20050100683A (ko) * 2003-02-13 2005-10-19 아스트라제네카 아베 5-ｆｕ 또는/및 ｃｐｔ-11과 ｚｄ6474의 병용 요법
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
PL1971338T3 (pl) * 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie ZD6474 i premetreksedu
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032651A1 (en) * 1999-11-05 2001-05-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397401A (zh) * 2016-08-30 2017-02-15 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法
CN106478598A (zh) * 2016-08-30 2017-03-08 山东罗欣药业集团股份有限公司 一种凡德他尼水合物晶体及其制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Also Published As

Publication number Publication date
IL161744A0 (en) 2005-11-20
EP1446124B1 (en) 2006-08-09
NO20042365L (no) 2004-06-07
DE60213845D1 (de) 2006-09-21
WO2003039551A1 (en) 2003-05-15
JP2005511597A (ja) 2005-04-28
US20050043395A1 (en) 2005-02-24
MXPA04004355A (es) 2004-08-11
DE60213845T2 (de) 2007-03-29
CA2464758C (en) 2010-09-28
JP4694127B2 (ja) 2011-06-08
GB0126879D0 (en) 2002-01-02
ATE335488T1 (de) 2006-09-15
CA2464758A1 (en) 2003-05-15
ZA200403455B (en) 2005-08-29
ES2269769T3 (es) 2007-04-01
NO328048B1 (no) 2009-11-16
PT1446124E (pt) 2006-12-29
HK1068546A1 (en) 2005-04-29
IL161744A (en) 2012-01-31
CN1612738A (zh) 2005-05-04
NZ532525A (en) 2006-11-30
KR100959607B1 (ko) 2010-05-27
CY1106259T1 (el) 2011-06-08
AU2002337382B2 (en) 2008-06-12
DK1446124T3 (da) 2006-11-13
KR20050043779A (ko) 2005-05-11
EP1446124A1 (en) 2004-08-18
AR037346A1 (es) 2004-11-03
US20120252827A1 (en) 2012-10-04
BR0213906A (pt) 2004-08-31

Similar Documents

Publication Publication Date Title
CN1298328C (zh) 包括应用zd6474和紫杉烷的联合疗法
CN1674905A (zh) 在癌症治疗中zd6474、血管内皮生长因子抑制剂和放射疗法的组合
CN1177833C (zh) 取代的间二氮杂萘衍生物
JP5563950B2 (ja) 組合せ療法
JP2019034949A (ja) Ｒｈｏキナーゼ阻害剤
AU2002337382A1 (en) Combination therapy comprising ZD6474 and a taxane
CN1665817A (zh) 制备某些吡咯并三嗪化合物的方法
CN1674938A (zh) 用于治疗癌症的vegf受体酪氨酸激酶抑制剂的组合
CN1898232A (zh) 用作抗血管发生剂的喹唑啉衍生物的马来酸盐
US8404839B2 (en) Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy} quinazoline difumarate Form A
CN100502866C (zh) 联合治疗
HK1068546B (en) Combination therapy comprising zd6474 and a taxane

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070207

Termination date: 20131106